Tue Feb 1, 2022 – 3:59 pm ESTTue Feb 1, 2022 – 4:39 pm EST
TOYKO (LifeSiteNews) – Japanese conglomerate and pharmaceuticals company Kowa found that ivermectin has an “antiviral effect” against the Omicron strain of coronavirus, the company announced Monday.
In a press release, Kowa said that the renowned anti-parasitic drug shows antiviral properties in a lab setting against the new variant and all other existing strains of the virus, including Alpha, Beta, Gamma, and Delta.
Researchers previously found that ivermectin inhibits replication and intracellular entry of coronavirus in laboratory studies, Kowa noted. The company added that it expects the drug to be applied as a therapeutic for all new coronavirus diseases.
Kowa has been investigating ivermectin as a treatment for COVID with Tokyo’s Kitasato University since 2021 and is currently testing the drug in a Phase III clinical trial, which ends in March. The conglomerate noted in Monday’s press release that Kitasato University professor Dr. Satoshi Omura, who shared the 2015 Nobel Prize in Physiology or Medicine for discovering ivermectin, directly requested that Kowa conduct the trials.
Omura has strongly supported the use of the ivermectin as a COVID-19 therapeutic. A paper he co-authored
The remainder of this article is available in its entirety at LifeSite News
The views expressed in this news alert by the author do not directly represent that of The Official Street Preachers or its editors
